Related Experiment Videos
[Current epilepsy treatment in adults]
A O Rossetti1, J-G Villemure, M Seeck
1Department of Neurology, Brigham and Women's Hospital, Boston, MA 02115, USA. arossetti@partners.org
Revue Medicale Suisse
|June 28, 2005
Summary
Epilepsy affects 1% of people, with two-thirds inadequately treated by antiepileptic drugs (AEDs). Newer AEDs offer better tolerability, guiding targeted treatment choices and considering invasive options for resistant cases.
Area of Science:
- Neurology
- Pharmacology
Context:
- Epilepsy affects approximately 1% of the global population.
- Current antiepileptic drug (AED) treatments achieve satisfactory seizure control in only two-thirds of patients.
- Novel AEDs present improved tolerability profiles compared to older medications.
Purpose:
- To review the efficacy and tolerability of existing and novel antiepileptic drugs.
- To discuss the strategic selection of AEDs in specific patient populations, including women of childbearing age and those with potential drug interactions.
- To evaluate the role and timing of invasive treatment strategies for drug-resistant epilepsy.
Summary:
- While new antiepileptic drugs (AEDs) have not significantly improved overall treatment efficacy, they offer enhanced tolerability.
- This improved tolerability facilitates personalized treatment selection, particularly for vulnerable patient groups.
- Early consideration of invasive epilepsy surgery is recommended for treatment-resistant cases, potentially leading to seizure remission.
Impact:
- Provides a framework for optimizing epilepsy management by balancing efficacy and tolerability.
- Highlights the importance of tailored therapeutic approaches for diverse patient needs.
- Informs clinical decision-making regarding the timely integration of advanced treatment modalities, including surgical interventions.